ERBB2 and breast cancer: T-DM1 treatment provides significant clinical benefit in breast cancer patients previously treated with chemotherapy and HER2-directed therapy, and in patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy [4,5,6,7].